Classification and characteristics of coagulase-negative, methicillin-resistant staphylococci.

Journal of Clinical Microbiology
B J WilkinsonS M Schaus

Abstract

Sixty-five clinical isolates of coagulase-negative, methicillin-resistant staphylococci have been classified as Staphylococcus epidermidis (63.0%), "phosphatase-negative S. epidermidis" (12.3%), coagulase-negative Staphylococcus aureus (6.2%), Staphylococcus hemolyticus (6.2%), Staphylococcus hominis (3.1%), and Staphylococcus warneri (1.5%). Five of the organisms (7.7%) could not be classified with certainty as currently recognized species. Novobiocin resistance was encountered in eight of the strains, but these were not classified as the accepted novobiocin-resistant staphylococcal species. Some differences in antibiotic resistance patterns to those typical of methicillin-resistant S. aureus were noted in that, although 29 strains were resistant to methicillin, penicillin, sulfamethizole, streptomycin, and tetracycline, the remainder of the strains were sensitive to streptomycin or tetracycline or both. In a majority of the strains (42 of 65), methicillin susceptibility testing by the disk method at 30 or at 37 degrees C in the presence of NaCl did not appear to enhance resistance expression. Most of the strains produced beta-lactamase (EC 3.5.2.6), but none of the 21 strains tested produced enterotoxin B.

References

Jan 1, 1979·Antimicrobial Agents and Chemotherapy·S SchaeflerD Jones
Jan 1, 1975·Journal of Clinical Microbiology·W E Kloos, K H Schleifer
May 1, 1977·Infection and Immunity·J J Iandolo, W M Shafer
Nov 1, 1978·Southern Medical Journal·W T SiebertT W Williams
Mar 1, 1975·Journal of Clinical Microbiology·K H Schleifer, W E Kloos
Apr 1, 1967·The Journal of Pathology and Bacteriology·C A Pennock, R B Huddy
Aug 1, 1952·American Journal of Clinical Pathology·T H HAIGHT, M FINLAND

❮ Previous
Next ❯

Citations

Aug 1, 1983·Journal of Clinical Microbiology·G D ChristensenE H Beachey
Sep 1, 1982·Journal of Clinical Microbiology·W E Kloos, J F Wolfshohl
Mar 1, 1982·Antimicrobial Agents and Chemotherapy·S B Price, D J Flournoy
Sep 1, 1986·Journal of Clinical Microbiology·G L WoodsC C Knapp
Mar 1, 1982·Journal of Clinical Microbiology·R H EngD Armstrong
Feb 1, 1983·Journal of Clinical Microbiology·L E NicolleG K Harding

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.